Jula K. Inrig

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes

Lynda A. Szczech, Huiman X. Barnhart, Jula K. Inrig et al. · Kidney International · 2008 · 515 citations · Full text

Pediatric Hematology, Medicine, Hematology +3

Use of Vancomycin or First-Generation Cephalosporins for the Treatment of Hemodialysis-Dependent Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia

Martín E. Stryjewski, Lynda A. Szczech, Danny Benjamin et al. · Clinical Infectious Diseases · 2006 · 342 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients

Jula K. Inrig, E.Z. Oddone, Vic Hasselblad et al. · Kidney International · 2007 · 210 citations

Hypertension, Hemodialysis, Cardiovascular Disease +11

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9